Skip to content

Clinical trial of optic nerve damage in acute retinal necrosis

Clinical trial of optic nerve damage in acute retinal necrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051972
Enrollment
Unknown
Registered
2021-10-11
Start date
2021-10-08
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute retinal necrosis

Interventions

Ganciclovir group:None
Control group:None

Sponsors

Qingdao Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with monocular ARN according to the diagnostic criteria established by the Japanese Acute Retinal Necrosis Research Group in 2015; 2.Aged 18 to 70 years.

Exclusion criteria

Exclusion criteria: 1.Severe refractive interstitial opacity affects the inspection; 2.The best corrected visual acuity of the other eye is less than 0.05; 3.Either eye has optic nerve disease; 4.Any eye has other eye diseases that may cause optic nerve damage, such as glaucoma, diabetic retinopathy, optic nerve damage caused by eye trauma, etc.; 5.Visual impairment is caused by nystagmus; 6.Patients who have received hormone therapy less than 1 month before enrollment or patients who have received any immunomodulatory agent or immunosuppressive agent less than 3 months before enrollment.

Design outcomes

Primary

MeasureTime frame
retinal nerve fiber layer thickness;best corrected visual acuity ;

Secondary

MeasureTime frame
visually-induced fluorescence;visual field;optic disc blood flow density;

Countries

China

Contacts

Public ContactWu Peipei

Qingdao Eye Hospital

ree04@126.com+86 18561623801

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026